Marbocyl P (10 kg)

10 x 10 pc

Tablet

Active substance

Marbofloxacin : 20 mg

ATC code

QJ01MA93 Marbofloxacin

QJ01MA Fluoroquinolones

QJ01M Quinolone and quinoxaline antibacterials

QJ01 Antibacterials for systemic use

QJ Antiinfectives for systemic use

Species

DOGS

Indications

Marbofloxacin is indicated in the treatment of:

- skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by susceptible strains of organisms.

- urinary tract infections (UTI) associated or not with prostatitis caused by susceptible strains of organisms.

- respiratory tract infections caused by susceptible strains of organisms.

Dose to be administered and administration route

For oral administration.

The recommended dose rate is 2 mg/kg/d ( 1 tablet for 10 kg per day) in single daily administration. To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.

- in skin and soft tissue infections, treatment duration is at least 5 days. Depending on the course of the disease, it may be extended up to 40 days.

- in urinary tract infections, treatment duration is at least 10 days.

Depending on the course of the disease, it may be extended up to 28 days.

- in respiratory infections, treatment duration is at least 7 days and depending on the course of the disease, it may be extended up to 21 days.

Adverse reactions

At the therapeutic recommended dosage, no severe side-effects are to be expected in dogs and cats. In particular, no lesions of the articular joints were encountered in clinical studies at the recommended dose rate. However, joint pain and/or neurological symptoms (ataxia, aggression, convulsion, depression) may occur on rare occasions.

Allergic reactions have been observed (temporary skin reactions) due to histamine release that may occur.

Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of treatment.

The frequency of adverse reactions is defined using the following convention:

- rare (more than 1 but less than 10 animals in 10,000 animals treated)